Compare Gap Inc (GAP) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs GSK plc — how do they compare? Gap Inc trades at $23.21 (market cap $8.21B), while GSK plc trades at $46.47 (market cap $91.88B). The key difference: GSK plc is far larger — about 11.2× Gap Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and GSK plc for 93 Days on average.
| GAP | GSK | |
|---|---|---|
Market Cap | $8.21B | $91.88B |
Volume | 5,192,917 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $61.18 |
52-Week Low | $18.35 | $43.24 |
Typical Hold Time | 37 Days | 93 Days |
Enterprise Value | $11.44B | $111.88B |
Dividend Yield | 3% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $23.61, down 0.76% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $25.67. The stock shows strong fundamentals with a low P/E of 7.04, robust ROE of 33.78%, and net income margin expansion to 8.14% in 2025. Recent earnings beats in Q1 and Q2 2026 and strategic moves into music partnerships signal brand revitalization efforts.
The outlook is positive given undervaluation, earnings momentum, and strategic initiatives, but risks include reliance on Old Navy's turnaround and competitive pressures. Upside to the price target offers potential, supported by institutional buying interest and solid cash flow generation.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
